Shokouh Meshkat

S. Meshkat (published as Meshkat S.) is a clinical researcher specialising in clinical trials and systematic studies of psychedelic and rapid‑acting antidepressant interventions. Available publications and trial records list Meshkat as a co‑investigator or author on multiple projects: randomized clinical trials evaluating repeated doses of psilocybin for treatment‑resistant depression, investigations of psilocybin‑assisted psychotherapy in bipolar II disorder, analyses assessing mystical or ‘‘peak’’ experiences as predictors of clinical response, comparative work on outcomes in participants who were unmedicated versus those who discontinued psychotropic medications for trial participation, and real‑world effectiveness studies of repeated intravenous ketamine infusions in transitional‑age youth. Meshkat is also represented on collaborative systematic reviews and methodological papers addressing reporting quality and pharmacokinetics relevant to psychedelic research.

Meshkat’s contributions lie at the intersection of clinical trial execution, outcome measurement and predictor analysis for psychedelic therapies. Their work emphasises pragmatic and translational questions—safety and effectiveness in real‑world and vulnerable populations (including bipolar II and transitional‑age groups), methodological rigour in trial conduct, and the role of subjective experience in therapeutic response. Publications indicate frequent collaboration within multidisciplinary teams, contributing to the growing evidence base and methodological standards for contemporary psychedelic medicine.